{"organizations": [], "uuid": "2c163118a8fe01ef4b69d53e5d706f64193cad01", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-submits-nda/brief-aerie-pharmaceuticals-submits-nda-to-u-s-fda-for-roclatantm-idUSASC0A273", "country": "US", "domain_rank": 408, "title": "BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.579, "site_type": "news", "published": "2018-05-15T19:00:00.000+03:00", "replies_count": 0, "uuid": "2c163118a8fe01ef4b69d53e5d706f64193cad01"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-submits-nda/brief-aerie-pharmaceuticals-submits-nda-to-u-s-fda-for-roclatantm-idUSASC0A273", "ord_in_thread": 0, "title": "BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aerie pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Aerie Pharmaceuticals Inc:\n* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%\n* AERIE PHARMACEUTICALS - EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS\n* AERIE PHARMACEUTICALS INC - NDA SUBMITTED AS A 505(B)(2) WITH AN EXPECTED TEN-MONTH FDA REVIEW Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T19:00:00.000+03:00", "crawled": "2018-05-16T18:48:27.005+03:00", "highlightTitle": ""}